CCIA
CBAY

Campbell & Co Investment Adviser’s Cymabay Therapeutics CBAY Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-21,714
Closed -$513K – 1428
2023
Q4 		$513K Sell
21,714
-14,401
-40% -$256K 0.05% 696
2023
Q3 		$538K Sell
36,115
-80,324
-69% -$1.06M 0.06% 483
2023
Q2 		$1.28M Buy
116,439
+36,960
+47% +$344K 0.23% 85
2023
Q1 		$693K Buy
+79,479
New +$636K 0.13% 291
2020
Q4 		– Sell
-33,800
Closed -$245K – 601
2020
Q3 		$245K Buy
+33,800
New +$181K 0.18% 258

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Campbell & Co Investment Adviser's CBAY Position: Q1 2024 in Review

Campbell & Co Investment Adviser sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 21,714 shares — an estimated $513K sold.

Campbell & Co Investment Adviser first reported a position in CBAY in Q3 2020 and held it in 5 quarters. The position peaked at $1.28M in Q2 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Campbell & Co Investment Adviser reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 21,714 Cymabay Therapeutics shares in Q1 2024, an estimated $513K.
  • Campbell & Co Investment Adviser first reported a position in Cymabay Therapeutics in Q3 2020 and held it in 5 quarters.
  • Campbell & Co Investment Adviser's Cymabay Therapeutics position peaked at $1.28M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2024, filed 10 May 2024.